Document:

<PAGE>
                                                                   Exhibit 10.85

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

                         AGREEMENT REGARDING SUBLICENSES

              (COULTER CORPORATION/COULTER PHARMACEUTICAL, INC.)

      This AGREEMENT REGARDING SUBLICENSES (the "Agreement") is made effective
as of December 2, 1998 (the "Effective Date") between Coulter Pharmaceutical,
Inc. ("CPI"), the Dana-Farber Cancer Institute, Inc. ("Dana-Farber"), and
Coulter Corporation ("Coulter").

                                   BACKGROUND

      WHEREAS, CPI is developing and intends to commercialize a
radioimmunotherapy (Bexxar(TM)) which includes an antibody known as B1 ("B1");

      WHEREAS, B1 was derived from a B1 hybrodoma and licensed by Dana-Farber to
Coulter for diagnostic applications pursuant to the Agreement between
Dana-Farber and Coulter dated July 23, 1981, as modified by the Modification
Agreement between Dana-Farber and Coulter dated March 1, 1983 and for
therapeutic applications pursuant to the agreement between Dana-Farber and
Coulter, dated April 28, 1983, as modified by the Modification Agreement No. 2
between Dana-Farber and Coulter, dated April 1, 1987, and the agreement between
Dana-Farber and Coulter, dated April 1, 1994 (the latter agreement referred to
hereinafter as the "'94 Agreement," and the foregoing five agreements
collectively referred to hereinafter as the "Prior Agreements").

      WHEREAS, Coulter granted CPI an exclusive sublicense to B1 for certain
therapeutic applications and a non-exclusive sublicense to B1 for certain
diagnostic applications pursuant to an Assignment Agreement dated February 24,
1995 (the "Assignment Agreement"), attached hereto as Attachment I, and to help
expedite and accelerate the process of commercialization, CPI would like to
grant further sublicenses of the sublicense for B1 granted to it by Coulter;

      WHEREAS, Coulter is willing to agree that CPI has such rights and
Dana-Farber is willing to agree that CPI has such rights, on the following terms
and conditions set forth in this Agreement;

      WHEREAS, Attachment II hereto sets forth provisions derived from the Prior
Agreements, with minor clarifications, which are pertinent to CPI and its
Sub-Sublicensee(s) (as hereinafter defined); and

      WHEREAS, the parties wish to provide additional clarifications in this
Agreement regarding the terms and conditions applicable to CPI and its
Sub-Sublicensee(s).

                                    AGREEMENT

      NOW, THEREFORE, intending to be legally bound, the parties hereby agree as
follows:

      1. Dana-Farber confirms and warrants that as set forth in the Prior
Agreements, Coulter holds a license to make, have made, use, offer for sale,
sell, have sold and import B1,
<PAGE>
and any related technical information licensed to Coulter under the Prior
Agreements, for diagnostic and therapeutic applications (the "B1 Technology")
and to use the hybridoma from which B1 was derived to accomplish such purposes.
Such license is currently valid, binding and in full force and effect and,
except as provided in Paragraph A of Attachment II, is exclusive to Coulter for
therapeutic and diagnostic applications as set forth in the Prior Agreements and
will remain exclusive to the extent permitted by the applicable statutes,
implementing regulations and policies of the Federal government, and any
agreements between Dana-Farber and the Federal government relating to the same,
including the Bayh Dole Act and any Institutional Patent Agreement(s), as they
may apply to the commercialization of the B1 Technology. Dana-Farber shall not
act in any manner inconsistent with Dana-Farber's grant of such exclusive
license to Coulter for the B1 Technology unless required or mandated to do so by
the Federal government. Coulter and CPI confirm and warrant to each other that
CPI has been granted a sublicense under the Assignment Agreement that is
currently valid, binding, and in full force and effect. No party to this
Agreement is aware of any breach of any term or condition of the Prior
Agreements as they pertain to the B1 Technology.

      2. Coulter and CPI represent and warrant that the Assignment Agreement,
reproduced in this Agreement as Attachment I and incorporated herein by
reference, contains all the terms and conditions governing CPI's rights and
obligations relating to B1 as between Coulter and CPI, and said rights permit
the further sublicense by Coulter of B1 Technology to Coulter Cellular
Therapies, Inc. for [*].

      3. Dana-Farber agrees that Coulter has the right to authorize CPI to grant
further sublicenses of the sublicense granted to CPI by Coulter pursuant to the
Assignment Agreement, so long as such further sublicenses are consistent with
the obligations of CPI set forth herein. Coulter hereby grants such
authorization to CPI. Such sublicenses may include the right for
Sub-Sublicensees to grant further sublicenses in a manner consistent with the
requirements of this Agreement. Coulter and CPI agree that the granting of such
sublicenses shall not be deemed to be an abandonment under Section 6 of the
Assignment Agreement. Coulter agrees that it is not hereby relieved of any
obligations that it continues to owe to Dana-Farber with respect to the B1
Technology under the Prior Agreements.

      4. Each party acknowledges and agrees that the terms and conditions under
which CPI holds a sublicense and may authorize the granting of further
sublicenses under a sub-sublicense agreement (a "Sub-Sublicense Agreement") are
set forth in this Agreement, including Attachment II, which is an integral part
of this Agreement. Dana-Farber and CPI agree that the obligations to Dana-Farber
of a sublicensee of CPI under any Sub-Sublicense Agreement are those set forth
in Paragraphs B, D, E and G of Attachment II (provided that royalties shall be
payable by CPI in respect of Net Sales made by CPI and all of the
Sub-Sublicensees) and that Dana-Farber retains the rights set forth in Paragraph
A of Attachment II. CPI agrees that it will insure that any Sub-Sublicensee
under a Sub-Sublicensee Agreement is aware of and will perform its obligations
under the paragraphs of Attachment II set forth in the preceding sentence and
under Section 7(b) of this Agreement. Further, CPI agrees and Coulter
acknowledges that Dana-Farber will be informed by written notice from CPI of the
identity of the Sub-Sublicensee(s).

----------------------------
* Confidential treatment requested

                                       -2-
<PAGE>
      5.

            (a) The parties acknowledge that the royalties owed to Dana-Farber
on the account of Net Sales of Licensed Products made by CPI or any
Sub-Sublicensee(s) are the royalties that Coulter would have owed to Dana-Farber
if Coulter had made such net Sales directly. CPI's royalty obligations to
Dana-Farber are governed by the terms set forth in this Section 5 and in
Paragraph C of Attachment II. CPI's obligations to pay royalties as provided in
this Section 5 shall commence on the date of first commercial sale of Licensed
Products by CPI or a Sub-Sublicensee and shall continue for so long as Licensed
Products are sold by CPI or a Sub-Sublicensee in the Territory. If the laws of
any foreign country(ies) within the Territory impose restrictions upon the
period of time that a licensor may receive royalties from its licensee(s) for
unpatented products such as B1, then CPI agrees to pay royalties on Net Sales of
Licensed Products in such country(ies) only for the maximum period of time
permitted by the law of such country(ies). For purposes of this Agreement, (A)
"Licensed Product" shall mean B1 and any product that contains B1, (B)
"Sub-Sublicensee" shall mean any corporation, partnership or business
organization to which CPI (or a further authorized sublicensee of CPI) grants
rights to enable such entity to sell Licensed Products, (C) "Territory" shall
mean all the countries of the world, and (D) "Net Sales" shall have the meaning
set forth in Paragraph C.2 of Attachment II.

            (b) Coulter and Dana-Farber acknowledge and agree that pursuant to
the Prior Agreement, Coulter paid to Dana-Farber advance royalty payments
totaling four million five hundred thousand United States dollars (US$4,500,000)
(the "Royalty Credit"). The parties agree that CPI will pay to Coulter the first
four million five hundred thousand United States dollars (US4,500,000) in
royalties payable pursuant to Section 5(c) of this Agreement. After the Royalty
Credit has been fully recovered by Coulter, either by its receipt of four
million five hundred thousand United States dollars (US$4,500,000) in cash or
CPI stock purchase according to the Assignment Agreement, CPI shall thereafter
make royalty payments directly to Dana-Farber, as set forth herein.

            (c) The royalties that shall be due and payable by CPI in respect of
the exercise of its rights under this Agreement and the Assignment Agreement
shall be as follows:

                  (i) On account of Net Sales of Licensed Products made by CPI
or any Sub-Sublicensee(s), CPI shall pay a royalty at the rate of [*] until [*]
and thereafter the royalty on Licensed Products shall be reduced to the rate of
[*].

                  (ii) CPI represents that it has an obligation to pay royalties
to the University of Michigan for certain patent rights transferred or licensed
by the University of Michigan to Coulter, including without limitation [*] which
relate to the use of an unlabeled and radiolabeled anti-CD20 antibody such as B1
in accordance with a radioimmunotherapy protocol the "Therapy Patents"). CPI
further represents that B1 will be offered for sale and sold by CPI and any
Sub-Sublicensee(s) for use in accordance with the invention(s) described and
claimed in the Therapy Patents. Based upon such representations, Dana-Farber
agrees that [*], with the result that royalties shall be payable to Dana-Farber
under this Agreement at the rate of [*] on

----------------------------
* Confidential treatment requested

                                      -3-
<PAGE>
Net Sales of Licensed Products in the United States in respect of which
royalties are also due and paid to the University of Michigan. However, no such
[*] shall be applied or allowed for any payments made to the University of
Michigan under said license in respect of Net Sales of Licensed Products outside
the United States. The parties further agree that [*] shall not have any effect
on the future construction or application of such Paragraph C.1 if CPI seeks any
further reduction in royalties in respect of any other third party technology.

                  (iii) The parties agree that in no event shall the royalty
rate on account of Net Sales of Licensed Products made by CPI or any
Sub-Sublicensee(s) be [*] either under this Section 5 or Paragraph C.1 of
Attachment II without the express written consent of Dana-Farber.

      6. CPI agrees that within sixty (60) days after execution of a
Sub-Sublicense Agreement, CPI will forward to Dana-Farber a summary of the
Sub-Sublicense Agreement and copies of those provisions of the Sub-Sublicense
Agreement that CPI reasonably believes are relevant to CPI's obligations to
Dana-Farber as provided herein which shall in any event include the provisions
of the Sub-Sublicense Agreement addressing the subject matter of the terms and
conditions identified in Paragraphs A, B, D, E and G of Attachment II.

      7. Coulter and CPI agree to the following insurance and indemnification
obligations.

            (a) COULTER'S INSURANCE AND INDEMNIFICATION OBLIGATIONS TO
DANA-FARBER: Coulter agrees that it is bound by the insurance and
indemnification obligations to Dana-Farber under Article XV of the '94 Agreement
and Article VIII of the '94 Agreement's Appendix A; and that such obligations
apply not only to the activities of Coulter and CPI, but also to the activities
of any of CPI's further sublicensee(s) pursuant to a sub-sublicense granted by
CPI. Coulter's obligations to Dana-Farber under Article XV of the '94 Agreement
and Article VIII of the '94 Agreement's Appendix A survive termination of this
Agreement or Coulter's license to the B1 Technology under the Prior Agreements.

            (b) CPI AND ANY FURTHER SUBLICENSEE(S)' INSURANCE AND
INDEMNIFICATION OBLIGATIONS TO COULTER: Because Coulter is obligated under
Section 7(a) to indemnify and defend Dana-Farber and to procure general
liability insurance as set forth in Article XV of the '94 Agreement and Article
VIII of the '94 Agreement's Appendix A, even as to claims, causes of action,
etc., that arise from CPI's activities or those of any Sub-Sublicensee(s), CPI
hereby agrees that it owes, and shall require that all further
Sub-Sublicensee(s) owe, insurance and indemnification obligations to Coulter
that are equal to the insurance and indemnification obligations to Dana-Farber
under Article XV of the '94 Agreement and Article VIII of the '94 Agreement's
Appendix A.

            (c) The parties agree that, for purposes of Sections 7(a) and 7(b)
hereof, Article XV of the '94 Agreement and Article VIII of the '94 Agreement's
Appendix A are hereby incorporated by reference as an integral part of this
Agreement.

----------------------------
* Confidential treatment requested

                                      -4-
<PAGE>
      8. Upon any termination of Coulter's license to the B1 Technology, this
Agreement will remain in full force and effect with CPI as the direct licensee
of Dana-Farber for the rights granted pursuant to the Assignment Agreement,
provided that:

            (a) CPI is not then in default of its obligations as provided
herein; and

            (b) CPI promptly agrees in writing to be bound by the insurance and
indemnification obligations Coulter has to Dana-Farber as set forth herein.

From and after the date on which CPI becomes a direct licensee of Dana-Farber,
upon any termination of CPI's license to the B1 Technology, any Sub-Sublicensee
that is not then in default of its obligations under its Sub-Sublicense
Agreement may elect by prompt written notice to Dana-Farber to retain the rights
granted to it under such Sub-Sublicense Agreement as a direct licensee of
Dana-Farber, provided that such Sub-Sublicensee agrees in writing to be bound by
the terms of this Agreement. Notice is considered promptly given if made by a
Sub-Sublicensee within thirty (30) days after written notice of termination of
CPI's license is provided to the Sub-Sublicensee by Dana-Farber.

      9. Dana-Farber acknowledges that CPI is bound only to those terms and
conditions contained herein, including those in Attachment II. To the extent
that the terms and conditions of this Agreement are inconsistent with the Prior
Agreements, this Agreement has a superseding effect as between Dana-Farber and
CPI. The parties acknowledge that this Agreement has been entered into in a good
faith effort to clarify the terms and conditions under which CPI is sublicensed
and authorized to grant further sublicenses for the B1 Technology and which CPI
is obligated to include in any Sub-Sublicense Agreement authorized hereunder.
This Agreement does not affect any positions as between Dana-Farber and Coulter
as regards the Prior Agreements, except with respect to the Royalty Credits and
the insurance and indemnification obligations set forth in Section 7(a) hereof.

      10. As of the date of this Agreement, Dana-Farber believes (without the
separate concurrence of CPI) that Federal law and policy requires that
antibodies comprising the B1 Technology to be leased or sold in the United
States must be manufactured substantially in the United States. CPI agrees to
seek to confirm its understanding that said requirement does not apply to such
B1 Technology, or in the alternative to cooperate with Dana-Farber to seek a
waiver of any such requirement as may exist. CPI acknowledges that Dana-Farber
cannot guarantee that such a waiver can be obtained. CPI shall bear all
reasonable costs associated with the seeking of such waiver by Dana-Farber and
shall be primarily responsible for preparing the documentation necessary to
support a waiver request. If such confirmation is not received and such waiver
is not granted, CPI shall comply with said requirement in such manner as may be
required by the United States government.

      11. Any notice or other communication required or permitted to be given to
any party hereto shall be in writing and shall be deemed to have been properly
given and to be effective on the date of delivery if delivered in person or five
(5) days after mailing by registered or certified mail, postage paid, or by
other courier with evidence of receipt to the other party(ies) as follows.

                                       -5-
<PAGE>
            (a) In the case of Dana-Farber, the proper address for all notices
and communications shall be:

            Director for Research
            Dana-Farber Cancer Institute, Inc.
            44 Binney Street
            Boston, MA  02115

            with a copy to:

            General Counsel
            Dana-Farber Cancer Institute, Inc.
            44 Binney Street
            Boston, MA  02115

or other individuals or addresses as shall hereafter be furnished by written
notice to the other parties hereto.

            (b) In the case of Counter, the proper address for all notices and
communications shall be:

            VP-Finance
            Coulter Corporation
            11800 Southwest 147th Avenue
            Miami, Florida  33196-2500

            with a copy to:

            Corporate Counsel
            Coulter Corporation
            11800 Southwest 147th Avenue
            Miami, Florida  33196-2500

or other individuals or addresses as shall hereafter be furnished by written
notice to the other parties hereto.

            (c) In the case of CPI, the proper address for all notices and
communications shall be:

            Coulter Pharmaceutical, Inc.
            550 California Avenue, Suite 200
            Palo Alto, CA  94306

            with a copy to:

            Cooley Godward LLP
            Attn:  James Kitch, Esq.
            Five Palo Alto Square

                                       -6-
<PAGE>
            3000 El Camino Real
            Palo Alto, CA  94306-2155

or other individuals or addresses as shall hereafter be furnished by written
notice to the other parties hereto.

      12.

            (a) Any controversy or claim arising out of, or relating to, any
provisions of this Agreement, or the breach thereof, which cannot otherwise be
resolved by good faith negotiations between the parties or by some form of
alternate dispute resolution other than arbitration shall be resolved by final
and binding arbitration in New York, New York under the rules of the American
Arbitration Association, or the Patent Arbitration Rules if applicable, then
obtaining.

            The arbitration shall be subject to the following terms:

                  (i) The number of arbitrators shall be one (1).

                  (ii) The arbitrator shall be an independent, impartial third
party having no direct or indirect personal or financial relationship to any of
the parties to the dispute, who has agreed to accept the appointment as
arbitrator on the terms set out in this Section 12.

                  (iii) The arbitrator shall be an active or retired attorney,
law professor or judicial officer with at least five (5) years experience in
general commercial matters and a familiarity with the laws governing proprietary
rights in intellectual property and the technology in dispute.

                  (iv) The arbitrator shall be selected as follows:

                        (1) Each party shall submit a description of the matter
to be arbitrated to the American Arbitration Association at its Regional Office
in New York, New York. Said Association shall submit to the parties a list of
the arbitrators available to arbitrate any dispute between them. Thereafter,
each party shall select, in numerical order, those persons on said list
acceptable as arbitrators and return the same to the Association. The first
arbitrator acceptable to all parties shall be deemed the selected arbitrator
with respect to the dispute then at issue under this Agreement. In the event of
a failure to select a mutually agreeable arbitrator, the Association shall be
requested to submit as many subsequent lists of arbitrators as shall be
necessary to effect a mutual selection.

                        (2) If the method of selection set out in paragraph
(iv)(1) fails for any reasons, then either party may petition any state or
federal court in New York having jurisdiction for appointment of the arbitrator
in accordance with applicable law, provided that the arbitrator must satisfy the
requirements of (ii) and (iii) above.

                  (v) The arbitrator shall announce the award in writing
accompanied by written findings explaining the facts determined in support of
the award and any relevant conclusions of law.

                                       -7-
<PAGE>
                  (vi) Unless otherwise provided in this Section or extended by
agreement of the parties, each party shall submit an initial request for
designation of an arbitrator within [*] after any request for arbitration,
the dispute shall be submitted to the arbitrator within [*] after the arbitrator
is selected and a decision shall be rendered within [*] after the dispute is
submitted.

                  (vii) The fees of the arbitrator and any other costs and fees
associated with the arbitration shall be paid in accordance with the decision of
the arbitrator.

                  (viii) The arbitrator shall have no power to add to, subtract
from, or modify any of the terms or conditions of this Agreement. Any award
rendered in such arbitration may be enforced by any party to the dispute in
either the courts of the State of New York or a United States District Court in
New York, New York, to whose jurisdiction for such purposes each party hereto
hereby irrevocably consents and submits.

            (b) Notwithstanding the foregoing, in the event that the controversy
or claim arises from an allegation that a termination under this Agreement was
not appropriate, the Agreement shall not be considered terminated until such
time as the arbitrator has made a determination that the termination was
appropriate.

            (c) Notwithstanding the foregoing, nothing in this Section 12 shall
be construed to waive any rights or timely performance of any obligations
existing under this Agreement.

      13. For the purpose of this Agreement and all services to be provided
hereunder, each party shall be, and shall be deemed to be, independent
contractors and not agents or employees of the other. No party shall have
authority to make any statements, representations or commitments of any kind, or
to take any action, that will be binding on another party hereto.

      14. If any one or more of the provisions of this Agreement shall be held
to be invalid, illegal or unenforceable, the validity, legality or
enforceability of the remaining provisions of this Agreement shall not in any
way be affected or impaired thereby.

      15. Neither this Agreement, not any part hereof, shall be assignable by
any party hereto without the express written consent of the other parties, which
consent shall not be unreasonably withheld. However, any party hereto may assign
this Agreement in connection with the merger, consolidation, transfer or sale of
all or substantially all of its assets. Any attempted assignment without such
consent shall be void.

      16. The validity and interpretation of this Agreement and the legal
relations of the parties to it shall be governed by the laws of the Commonwealth
of Massachusetts.

      17. The parties agree that they have participated equally in the formation
of this Agreement and that the language herein should not be presumptively
construed against any party hereto.

----------------------------
* Confidential treatment requested

                                       -8-
<PAGE>
      18. No change, modification, extension, termination or waiver of any of
this Agreement and provisions herein containing any obligations owed
Dana-Farber, shall be valid unless made in writing and signed by a duly
authorized representative of each party.

      19. This Agreement may be executed in one or more counterparts, each of
which shall be an original and all of which shall constitute together the same
document.

      IN WITNESS WHEREOF, Dana-Farber, Coulter and CPI have executed this
Agreement in triplicate originals by their respective authorized officers as of
the Effective Date.

DANA-FARBER CANCER INSTITUTE, INC.

By: /s/ RUTH EMYANITOFF, PH.D.

Name: Ruth Emyanitoff, Ph.D.

Title: Director, Office of Technology

COULTER CORPORATION                       COULTER PHARMACEUTICAL, INC.

By: /s/ EUGENE L. BABCOCK                 By: /s/ MICHAEL F. BIGHAM

Name: Eugene L. Babcock                   Name: Michael F. Bigham

Title:Vice President, Finance             Title:

                                      -9-
<PAGE>
*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

                                  ATTACHMENT I

                              ASSIGNMENT AGREEMENT
                                     BETWEEN
                               COULTER CORPORATION
                                       AND
                          COULTER PHARMACEUTICAL, INC.
                          DATED AS OF FEBRUARY 24, 1995

The full text of Attachment I was originally attached to the registration
statement of Coulter Pharmaceutical, Inc. on Form S-1 (File No. 333-17661) filed
with the Commission on December 11, 1996. Pursuant to a confidential treatment
request submitted to the Commission by Coulter, the Commission granted
confidential treatment with respect to certain terms of the Assignment
Agreement.
<PAGE>
*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

                                  ATTACHMENT II

                         LICENSING TERMS AND CONDITIONS
                   BINDING ON CPI AND FURTHER SUBLICENSEES

      A.    RETAINED RIGHTS.

      Dana-Farber retains the right to use the B1 Technology [*].
Dana-Farber further retains the right [*] .

      The rights and licenses confirmed in Section 1 of this Agreement are
subject to, where applicable, a nonexclusive license to the United States
government to the extent required by Federal law and policy.

      B.    DUE DILIGENCE.

      CPI shall [*] to diligently make a therapeutic product based upon the B1
Technology available to the general public.

      CPI shall provide annual reports to Dana-Farber on its specific goals and
objectives for commercializing the B1 Technology. Such reports shall be provided
on January 15 of each year or on such other date as CPI and Dan-Farber mutually
agree to in writing.

      C.    ROYALTIES.

            1. CPI has the right to enter into Sub-Sublicense Agreements with
other entities for the rights, privileges and licenses that CPI holds as set
forth in the Assignment Agreement and this Agreement, at royalty rates [*].
Where CPI must obtain a license from a third party in order to practice the B1
Technology, either [*], then the otherwise applicable royalty rate shall [*] to
the extent that CPI or its Sub-Sublicensee actually pays royalties to the third
party, but in no event will the royalty rate be [*] either under Section 5 of
this Agreement or this Paragraph C.1.

            2.    "Net Sales" shall mean [*]:

       (A)   [*];

       (B)   [*];

       (C)   [*]; and

       (D)   [*].

      Licensed Products shall [*].

----------------------------
* Confidential treatment requested
<PAGE>
      In the event CPI enters into a Sub-Sublicense Agreement that contains a
different definition of Net Sales, subject to the approval of Dana-Farber, CPI
may utilize such definition in the calculation and reporting of royalties
hereunder. Dana-Farber agrees [*].

            3. Subject to Section 5(b) of this Agreement, the payment of
royalties shall be made by CPI to Dana-Farber within [*] after March 31, June
30, September 30 and December 31 each year during the term of this Agreement
covering the quantity of Licensed Products sold by CPI or its Sub-Sublicensee(s)
during the preceding calendar quarter. All payments to be made hereunder shall
be paid in United States dollars in Boston, Massachusetts, or at such other
place and in such other way, as Dana-Farber may reasonably delegate, without
deduction of exchange, collection or other charges. For the purpose of
determining royalties due to Dana-Farber, Net Sales made in currencies other
than United States dollars will be converted to United States dollars at the
exchange rate quoted in the Wall Street Journal on the last day of the calendar
quarter in which such Net Sales were made [*]. Only a single royalty shall be
paid with respect to any Licensed Product, irrespective of the number of claims
of patent rights or technical information. In the event that any payment due
hereunder is not made when due, the payment shall accrue interest beginning on
the first day following the due date as herein specified, calculated at the
annual rate of the sum of (a) [*] plus (b) the prime interest rate quoted by the
Bank of Boston on the date said payment is due, the interest being compounded on
the last day of each calendar quarter, provided that in no event shall said
annual rate exceed the maximum legal rate in Massachusetts. The payment of such
interest shall not foreclose Dana-Farber from exercising any other rights it may
have as a consequence of the lateness of any payment. Should CPI fail to pay
Dana-Farber such royalties as are due and payable hereunder, Dana-Farber shall
have the right to terminate the license on [*] written notice, unless CPI shall
pay Dana-Farber within the [*] notice period all such royalties and interest
that are due and payable. Upon the expiration of the [*] period, if CPI shall
not have paid all such royalties and interest due and payable, Dana-Farber, at
its sole option, may immediately terminate this Agreement and all rights,
privileges and license granted hereunder.

      D. REPORTS AND RECORDS.

      Within [*] after March 31, June 30, September 30 and December 31 of each
year in which this Agreement is in effect, CPI shall deliver to Dana-Farber
full, true and accurate reports of its activities and those of its
Sub-Sublicensee(s), if any, relating to this Agreement during the preceding
three (3) month period. These reports shall include at least the following:

      (A)   Number of Licensed Products sold;

      (B)   Total billings for Licensed Products sold, where applicable;

      (C)   Deductions applicable to a determination of Net Sales; and

      (D)   Total royalties due.

      Coulter and CPI shall keep, and CPI shall require any Sub-Sublicensee(s)
to keep, true books of account containing an accurate record of all data
necessary for the determination of the

----------------------------
* Confidential treatment requested

                                      -2-
<PAGE>
amounts payable to Dana-Farber, including the amounts of the Royalty Credit.
Such records (including information received from any Sub-Sublicensee(s)) shall
be kept at each entity's principal place of business, or the principal place of
business of the appropriate division of the entity for which records are being
maintained. Said records shall be available for inspection by a certified public
accountant, selected by Dana-Farber and reasonably acceptable to the applicable
entity during regular business hours for three (3) years following the end of
the calendar year to which they pertain, in order for Dana-Farber to ascertain
the correctness of any report and/or payment. The provisions of this paragraph
shall survive termination of this Agreement.

      E.    WARRANTIES, REPRESENTATION AND DISCLAIMERS.

      DANA-FARBER DOES NOT WARRANT THE VALIDITY OF ANY PATENT RIGHTS WHICH MAY
BE LICENSED PURSUANT TO THIS AGREEMENT AND MAKES NO REPRESENTATION WHATSOEVER
WITH REGARD TO THE SCOPE OF ANY PATENT RIGHTS OR THAT SUCH PATENT RIGHTS MAY BE
EXPLOITED BY COULTER OR AFFILIATE(S) OR SUBLICENSEE(S) OF COULTER WITHOUT
INFRINGING OTHER PATENTS; PROVIDED HOWEVER, THAT DANA-FARBER REPRESENTS AND
WARRANTS THAT IT SHALL TAKE NO ACTION WHICH SHALL JEOPARDIZE ANY SUCH PATENT
RIGHTS AND HAS NO KNOWLEDGE OF ANY THIRD PARTY RIGHTS TO A LICENSED TECHNOLOGY
OTHER THAN RIGHTS HERETOFORE GRANTED TO THE UNITED STATES GOVERNMENT. IF
UNPATENTED BIOLOGICAL MATERIALS ARE LICENSED HEREUNDER, DANA-FARBER MAKES NO
REPRESENTATION THAT SUCH MATERIALS OR THE METHODS USED IN MAKING OR USING SUCH
MATERIALS ARE FREE FROM LIABILITY FOR PATENT INFRINGEMENT.

      DANA-FARBER MAKES NO WARRANTY, EXPRESS OR IMPLIED, INCLUDING, WITHOUT
LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR OF FITNESS FOR A
PARTICULAR PURPOSE WITH RESPECT TO ANY PATENT, NONPUBLIC OR OTHER INFORMATION,
OR TANGIBLE RESEARCH PROPERTY, LICENSED OR WHICH OTHERWISE MAY BE PROVIDED TO
COULTER AND HEREBY DISCLAIMS THE SAME.

      F.    TERM AND TERMINATION.

      Unless earlier terminated under the appropriate agreement, the license
shall remain an exclusive license and in full force and effect as long as
Licensed Products are being developed or sold.

      If any party defaults in the performance of its obligations under this
Agreement and fails to remedy the default within [*] for financial
obligations and [*] for non-financial obligations after written notice from the
non-defaulting party to which an obligation was owed, the non-defaulting party
is entitled upon the giving of written notice to immediately terminate this
Agreement; however, if the defaulting party has undertaken and continues to
undertake good faith efforts to cure, the defaulting party will be granted
another [*] to cure.

----------------------------
* Confidential treatment requested

                                       -3-
<PAGE>
      If CPI, directly or indirectly through its sublicensee(s), ceases to carry
on its business with respect to the B1 Technology at any time prior to
commercial launch of the Licensed Products in the United States, CPI shall give
prompt written notice to Coulter and Coulter shall thereafter have one hundred
and twenty (120) days for its right of first offer to reacquire the B1
Technology as set forth in Section 6 of the Assignment Agreement. If Coulter
does not so exercise such right of first offer, then Dana-Farber has the right
to terminate this Agreement and to narrow its license to Coulter of the B1
Technology under the Prior Agreements to remove from such license the rights
granted by Coulter to CPI pursuant to the Assignment Agreement.

      Upon termination of this Agreement for any reason, nothing herein shall be
construed to release any party from any obligation that matured prior to the
effective date of such termination. CPI and any Sub-Sublicensee(s) thereof may,
after the effective date of such termination, sell all Licensed Products which
are in inventory at the time of termination, and complete and sell Licensed
Products which CPI can clearly demonstrate were in the process of manufacture at
the time of such termination, provided that CPI shall pay to Dana-Farber the
royalties thereon as required by this Agreement and shall submit the reports
required by Paragraph D of this Attachment II on the Net Sales of Licensed
Products.

      G.    RESTRICTION ON USE OF NAMES.

      CPI and its Sub-Sublicensee(s) shall not use the names of Dana-Farber, its
related entities, Dr. Schlossman and other employees of Dana-Farber, or any
adaptations thereof, in any advertising, promotional or sales literature,
without the prior written consent of Dana-Farber in each case; provide however,
that Coulter and its sublicensee(s) (a) may refer to publications by employees
of Dana-Farber in the scientific literature or (b) may state that a license from
Dana-Farber has been granted as herein provided.

                                       -4-<PAGE>
                                                                   Exhibit 10.86

*Certain confidential information contained in this document, marked by
brackets, has been omitted and filed with the Securities and Exchange Commission
pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended

                           COMMERCIALIZATION AGREEMENT

      This is an Agreement, effective as of the 1st day of November, 1994 (the
EFFECTIVE DATE), between Coulter Corporation, a corporation incorporated in the
State of Delaware, with offices located at 11800 S.W. 147 Avenue, Miami, Florida
33196 ("COULTER"), and the Regents of the University of Michigan, a
constitutional corporation of the State of Michigan, with offices located at
3003 South State, Room 2071, Ann Arbor 48109-1280 ("MICHIGAN"). COULTER and
MICHIGAN agree as follows:

1.    BACKGROUND.

      1.1 MICHIGAN undertakes biological research in order to understand and
develop strategies to address the pathogenesis of cancer and other human
disease. COULTER utilizes new scientific discoveries to serve humanity by
developing commercial products for use by research scientists and for the
diagnosis and treatment of diseases.

      1.2 Researchers employed by COULTER and those employed by MICHIGAN have
jointly invented LICENSED PATENTS that are identified and defined below. COULTER
desires to commercialize LICENSED PRODUCTS that are identified and defined
below. Both COULTER and MICHIGAN desire to make the benefits of the LICENSED
PRODUCTS available to the public.

      1.3 MICHIGAN and COULTER believe that exclusive rights are an important
factor with regard to the ability to market the LICENSED PRODUCTS, and both
Parties have determined that in order to best effectuate the commercialization
of the LICENSED PRODUCTS, the exclusive right to the LICENSED PATENTS needs to
be held and promoted by COULTER. To this end and for the benefit of both
MICHIGAN and COULTER, MICHIGAN, in accordance with the terms and conditions of
this Agreement and consistent with its mission of education and research, is
agreeing to refrain from exercising its rights to license the LICENSED PRODUCTS
to third parties; and COULTER, in consideration for the benefits thereby gained,
is agreeing to share the benefits and revenues resulting from commercialization
of the LICENSED PRODUCTS.

2.    DEFINITIONS.

      2.1 "TECHNOLOGY," as used in this Agreement, shall mean

            A. All information (including by way of example and not limitation,
any manufacturing techniques, data, designs, or methods; and also including
know-how and other information, whether or not protected by patents relating to
manufacture, use and marketing), covering the method of radioimmunotherapy of
lymphoma developed by MICHIGAN's employees Mark Kaminski and Richard Wahl as
described in MICHIGAN'S Technology Management Office File #1009, a copy of which
is attached hereto as Exhibit A; and which encompasses:
<PAGE>
            B. All information encompassed in U.S. Patent Application No.
08/121,582, filed September 15, 1993 entitled "Radioimmunotherapy of Lymphoma
Using the Anti-CD20 Antibodies," invented by MICHIGAN's employees Mark Kaminski
and Richard Wahl and by COULTER's employees Gregory Butchko and Stephan Glenn.

      2.2 "LICENSED PATENT(S)" shall mean:

            A. All patents and patent applications encompassing U.S. Patent
Application No. 08/121,582, filed September 16, 1993 entitled
"Radioimmunotherapy of Lymphoma Using Anti-CD20 Antibodies," invented by
MICHIGAN's employees Mark Kaminski and Richard Wahl and by COULTER's employees
Gregory Butchko and Stephan Glenn, and

            B. All future patents and patent applications which cover an
invention included in the TECHNOLOGY,

            C. All foreign equivalent patent applications and Patent Cooperation
Treaty filings, and all patents issuing therefrom, which cover an invention
included in the TECHNOLOGY, and

            D. All divisionals, continuations-in-part, continuations, reissues,
renewals, extensions or additions to any such patents.

      2.3 "VALID CLAIM(S)" means:

            A. Any claim(s) in an unexpired patent or pending in a patent
application included within the LICENSED PATENTS which has not been held
unenforceable, unpatentable, or invalid by a decision of a court or other
governmental agency of competent jurisdiction, unappealable or, unappealed
within the time allowed for appeal, and which has not been admitted to be
invalid or unenforceable through reissue or disclaimer.

            B. In any patent application which includes claims that encompass
the invention described by U.S. Patent Application No. 08/121,582, filed
September 15, 1993 entitled "Radioimmunotherapy of Lymphoma Using the Anti-CD20
Antibodies," [*].

      2.4 "LICENSED PRODUCT(S)" shall mean:

            A. Any product(s) whose manufacture, use or sale in any country
would, but for the ownership of or a license under LICENSED PATENTS, comprise an
infringement, including contributory infringement, of one or more VALID CLAIMS,
and

            B. Any product which incorporates, is produced by or utilizes the
TECHNOLOGY.

      2.5 "FIELD OF USE" shall refer to any field of use for which the LICENSED
PRODUCTS may be designed, manufactured, used and/or marketed under this
Agreement.

----------------------------
* Confidential treatment requested

                                      -2-
<PAGE>
      2.6 "TERRITORY" shall mean all countries of the world.

      2.7 "NET SALES" shall mean the revenue derived by [*]:

          A.    [*];

          B.    [*];

          C.    [*];

          D.    [*].

      [*]

      2.8 "ROYALTY QUARTER(S)" shall mean the three-month periods ending on the
last day of MARCH, JUNE, SEPTEMBER and DECEMBER each year.

      2.9 "PARTIES" in singular or plural usage, as required by the context
shall mean COULTER and/or MICHIGAN.

      2.10 "AFFILIATE(S)" shall mean any corporation or other business entity
controlled by, controlling, or under common control with COULTER. For this
purpose, "control" means direct or indirect beneficial ownership of greater than
fifty percent (50%) interest in the income or stock of such corporation or other
business.

      2.11 "SUBLICENSEE(S)" shall mean any person or entity, except an
AFFILIATE, sublicensed by COULTER under this Agreement to make, have made, use,
market or sell LICENSED PRODUCTS.

3.    GRANT OF EXCLUSIVITY.

      3.1 MICHIGAN agrees not to license any rights under the TECHNOLOGY to any
third party.

      3.2 MICHIGAN grants to COULTER the exclusive right and license to make,
have made, use, lease and sell the LICENSED PRODUCTS in the TERRITORY for the
FIELD OF USE for the term of this Agreement with the right to grant sublicenses
(as used herein, referring both to the sublicense of MICHIGAN's rights granted
to COULTER, and to the license of COULTER's rights) to AFFILIATES and
SUBLICENSEES. COULTER agrees to grant such sublicenses in accordance with the
terms of Article 8 below.

4.    CONSIDERATION.

      4.1 COULTER shall pay to MICHIGAN a one time license issue fee [*]. The
license issue fee shall be credited against royalties due MICHIGAN provided in
this ARTICLE 4. The license issue fee shall be nonrefundable.

----------------------------
* Confidential treatment requested

                                       -3-
<PAGE>
      4.2 COULTER shall pay to MICHIGAN a royalty equal to [*] of NET SALES
of LICENSED PRODUCTS which are covered by one or more VALID CLAIM(S) (that is,
for LICENSED PRODUCTS which are described by Paragraph 2.4A).

      4.3 If the LICENSED PRODUCTS are not covered by one or more VALID
CLAIM(S), but only incorporates non-patented TECHNOLOGY (that is, for LICENSED
PRODUCTS which are not described by Paragraph 2.4A), COULTER shall pay to
MICHIGAN a royalty equal to [*] of NET SALES of LICENSED PRODUCTS for a period
of [*] from the date of commercialization of LICENSED PRODUCTS.

      4.4 Only a single royalty shall be paid with respect to any LICENSED
PRODUCT, irrespective of the number of VALID CLAIMS, LICENSED PATENTS or
TECHNOLOGY utilized.

      4.5 COULTER shall pay to MICHIGAN an annual Agreement maintenance fee.
This annual fee shall accrue in the ROYALTY QUARTER ending June 30th of the
years specified below, and shall be due and payable and included with the report
for that quarter. Each annual fee can be credited by COULTER in full against all
royalties to be paid to MICHIGAN.

      The annual maintenance fees shall be as follows:

            A. In full calendar years [*] this Agreement, the annual maintenance
fee shall be [*] per year.

            B. By the maintenance fee due date of the [*] of this Agreement [*],
COULTER must have [*].

                  (1) If Coulter has not [*], then the maintenance fee will be
[*] per year until [*].

                  (2) The PARTIES will renegotiate in good faith [*].

            C. After the [*], the maintenance fee will revert to [*] for the
time remaining to the end of [*].

      4.6 COULTER shall pay to MICHIGAN annual minimum royalty fees. This annual
fee shall accrue in the ROYALTY QUARTER ending March 31st of the calendar years
of this Agreement specified below, and shall be due and payable and included
with the report for that quarter. Each annual fee can be credited by COULTER in
full against all royalties otherwise to be paid to MICHIGAN in the future.

      Minimum royalties fees will be due MICHIGAN as follows:

            A.  [*]

                [*]

----------------------------
* Confidential treatment requested

                                       -4-
<PAGE>
                [*]

                [*]

                [*]

            B. In a year that [*], the parties will renegotiate in good faith
the requirement of minimum royalties due MICHIGAN [*].

      4.7 Where COULTER must obtain a license from a third party in order to
practice the subject TECHNOLOGY, either because the commercial utility of such
TECHNOLOGY is dependent upon third party intellectual property or because there
is a good faith determination by COULTER that practice of the TECHNOLOGY can
subject COULTER to an infringement action, then the royalty rate provided in
Sections 4.2 and 4.3 shall be reduced by [*], but only with respect to
royalties due upon LICENSED PRODUCTS covered by such third party licenses.

5.    REPORTS.

      5.1 COULTER shall keep and require AFFILIATES and SUBLICENSEES to keep
true and accurate records and books of account containing data reasonably
required for the computation and verification of, payments to be made as
provided by this Agreement, which records and books shall be open for inspection
upon reasonable notice during business hours by an independent certified
accountant selected by MICHIGAN, for the purpose of verifying the amount of
payments due and payable. Said right of inspection will exist for three (3)
years from the date of origination of any such record, and this requirement and
right of inspection shall survive any termination of this Agreement (this right
shall not be deemed to foreshorten any statute of limitations applicable to any
claim). MICHIGAN shall be responsible for all expenses of such inspection,
except that if such inspection [*], then said inspection shall be at COULTER's
expense and [*] shall become due and payable to MICHIGAN.

      5.2 Within [*] after March 31, June 30, September 30 and December 31,
during the term of this agreement (including the close of any ROYALTY QUARTER
immediately following any termination of this Agreement), COULTER shall report
to MICHIGAN true and accurate reports of its and its AFFILIATES' and
SUBLICENSEES' activities relating to this AGREEMENT during the ROYALTY QUARTER
period. If no royalties are due, COULTER shall so report. These reports shall
include at least the following:

            A. Number of LICENSED PRODUCTS sold or otherwise generating NET
SALES (to be reasonably identified and segregated by type, in reports and in
internal records above), and country of sale of LICENSED PRODUCTS;

            B. Total billings for LICENSED PRODUCTS, and any other revenues
included in NET SALES;

            C. Deductions applicable to a determination of NET SALES;

----------------------------
* Confidential treatment requested

                                       -5-
<PAGE>
            D. Any data, amounts and calculations used in the special
calculations of NET SALES for certain AFFILIATES as provided in the Note under
Paragraph 2.7 (with, for reference, the transfer sales amounts received by
COULTER from the AFFILIATE): and

            E. Total royalties due.

6.    PAYMENTS.

      6.1 COULTER shall pay to MICHIGAN the royalties due and payable (those
royalties accrued during each ROYALTY QUARTER) in United States Dollars in Ann
Arbor, Michigan and such payment shall be included with each quarterly report.
COULTER agrees to make all payment due hereunder to MICHIGAN by check made
payable to "The Regents of the University of Michigan," and sent to the address
for notices set forth in ARTICLE 19 herein.

      6.2 On all amounts outstanding and payable to MICHIGAN, interest shall
accrue from the date such amounts are due and payable [*] at such lower
rate as may be required by law.

      6.3 Where NET SALES are received in foreign currency, the foreign currency
shall be converted into its equivalent in United States dollars at the exchange
rate of such currency as reported (or if erroneously reported, as subsequently
corrected) in the Wall Street Journal on the last business day of the ROYALTY
QUARTER during which such payments are received by COULTER or AFFILIATES (or if
not reported on that date, as quoted by the Chase Manhattan Bank, N.A., in New
York City, New York).

7.    COMMERCIALIZATION.

      7.1 It is understood that COULTER has the responsibility to [*]. COULTER
agrees to [*].

      7.2 It is further understood that MICHIGAN [*].

      7.3 To the extent that such obligation must be required of COULTER by
MICHIGAN pursuant to 37 CFR 401.14 and other law relating to the licensing of
results of federally sponsored research, the following obligation applies:
COULTER agrees to substantially manufacture or have manufactured all LICENSED
PRODUCTS in the United States. If United States manufacture of any LICENSED
PRODUCT is not commercially feasible, then MICHIGAN will cooperate with COULTER
in obtaining waivers of this requirement from the United States Government.

8.    SUBLICENSING BY COULTER.

      8.1 COULTER shall have the exclusive right to grant sublicenses to its
ownership rights and privileges under the LICENSED PATENTS and TECHNOLOGY to its
AFFILIATES and SUBLICENSEES, to make, have made, use, market and sell, in the
TERRITORY, LICENSED PRODUCTS designed and marketed solely for use in the FIELD
OF USE.

----------------------------
* Confidential treatment requested

                                      -6-
<PAGE>
      8.2 MICHIGAN shall be informed by written notice of the identity of each
SUBLICENSEE and AFFILIATE.

      8.3 COULTER agrees that any sublicenses granted by it shall be consistent
with the terms of this Agreement, and shall contain acknowledgements by the
SUBLICENSEE or sublicensed AFFILIATE of MICHIGAN's rights in the TECHNOLOGY and
LICENSED PATENTS, and the disclaimer of warranty and limitation on MICHIGAN's
liability, as provided by Article 11 below. All sublicenses shall also contain
provisions under which the SUBLICENSEE or sublicensed AFFILIATE accepts duties
to keep records; to avoid improper representations or responsibilities; to
defend, hold harmless, and indemnify MICHIGAN; to comply with laws; and to
restrict the use of MICHIGAN's name; which duties shall be at least equivalent
to those accepted by COULTER in Paragraphs 5.1, 11.4 and 12.1, and articles 16,
and 17, respectively, herein.

      8.4 Reporting and payment of such royalties shall be made by COULTER in
accordance with the provisions of ARTICLE 5 REPORTS and ARTICLE 5 PAYMENTS.

      8.5 COULTER agrees to forward to MICHIGAN copies of such reports as
received by COULTER from its AFFILIATES and SUBLICENSEES as shall be pertinent
to a royalty accounting, with COULTER's reports for the relevant ROYALTY QUARTER
to which such reports relate.

9.    PATENT APPLICATIONS AND MAINTENANCE.

      9.1 MICHIGAN recognizes that COULTER has filed a patent application on
MICHIGAN and COULTER's behalf, which is LICENSED PATENTS U.S. Patent Application
No. 08/121,582, filed September 16, 1993 entitled Radioimmunotherapy of Lymphoma
Using Anti-CD20 Antibodies invented by MICHIGAN's employees Mark Kaminski and
Richard Wahl and by COULTER's employees Gregory Butchko and Stephan Glenn.
COULTER [*] of said patent application and any resulting patent, as well as
all other LICENSED PATENTS as may be applied for (though this is not in itself
intended as an obligation for COULTER to file new patent applications), provided
that:

            A. [*];

            B. [*];

            C. [*]; and

            D. [*].

      9.2 COULTER agrees to reasonably file, prosecute and maintain such patent
applications and patents as will, in its reasonable opinion, contain legally
viable VALID CLAIMS covering any commercially valuable TECHNOLOGY.

----------------------------
* Confidential treatment requested

                                       -7-
<PAGE>
      9.3 The PARTIES acknowledge that because [*] is [*] to COULTER, COULTER
may not desire to [*], and may choose to [*] in a manner which will require [*].

      9.4 The PARTIES acknowledge a good faith duty to cooperate in the
prosecution of Licensed Patents with a common goal of seeking broad,
commercially useful patent protection.

10.   INFRINGEMENT.

      10.1 Should either PARTY desire to enforce the LICENSED PATENTS against
infringement by third parties, including defending any action for declaratory
judgment of noninfringement or invalidity, and filing, prosecuting, defending
and settling infringement and declaratory judgment actions, then that PARTY
shall notify the other, [*].

      10.2 [*].

11.   NO Warranties; LIMITATION ON MICHIGAN'S LIABILITY.

      11.1 MICHIGAN, including its fellows, officers, employees and agents,
makes no representations or warranties that any LICENSED PATENT is or will be
held valid, or that the manufacture, use, sale or other distribution of any
LICENSED PRODUCT will be held valid, or that the manufacture, use, or sale or
other distribution of any LICENSED PRODUCT will not infringe upon any patent or
other rights not vested in MICHIGAN or COULTER. MICHIGAN represents that it has
no knowledge of any third party rights in TECHNOLOGY.

      11.2 MICHIGAN, INCLUDING ITS FELLOWS, OFFICERS, EMPLOYEES AND AGENTS,
MAKES NO REPRESENTATIONS, EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, INCLUDING BOTH NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY
OR FITNESS FOR A PARTICULAR PURPOSE, AND ASSUMES NO RESPONSIBILITIES WHATEVER
WITH RESPECT TO DESIGN, DEVELOPMENT, MANUFACTURE, USE, SALE OR OTHER DISPOSITION
BY COULTER, AFFILIATES OR SUBLICENSEES OF LICENSED PRODUCTS.

      11.3 The entire risk as to performance of the LICENSED PRODUCT is assumed
by COULTER, AFFILIATES AND SUBLICENSEES. In no event shall MICHIGAN, including .
its fellows, officers, employees and agents, be responsible or liable for any
direct, indirect, special, incidental, or consequential damages or lost profits
to COULTER, AFFILIATES, SUBLICENSEES, or any other individual or entity
regardless of legal theory. The above limitations on liability apply even though
MICHIGAN, its fellows, officers, employees or agents may have been advised of
the possibility of such damage.

      11.4 COULTER will not make any statements, representations or warranties
or accept any liabilities whatsoever to or with regard to any person or entity
which are inconsistent with any disclaimer or limitation included in this
Article 11. COULTER will require written agreement with its sublicensed
AFFILIATES and SUBLICENSEES that they will not make any statements,
representations or warranties or accept any liabilities whatsoever to or with
regard to any person or entity which are inconsistent with any disclaimer or
limitation included in this Article 11.

----------------------------
* Confidential treatment requested

                                       -8-
<PAGE>
12.   INDEMNITY; INSURANCE.

      12.1 COULTER shall defend, indemnify and hold harmless and shall require
its AFFILIATES and SUBLICENSEES to defend, indemnify and hold harmless MICHIGAN,
its fellows, officers, employees and agents, for and against any and all claims,
demands, damages, losses, and expenses of any nature (including attorneys' fees
and other litigation expenses), resulting from, but not limited to, death
personal injury, illness, property damage, economic loss or products liability
arising from or in connection with, (i) manufacture, use, sale or other
disposition by COULTER, AFFILIATES of SUBLICENSEE of LICENSED PRODUCTS; (ii) the
direct or indirect use by any person of LICENSEES; (iii) the use by COULTER,
AFFILIATES or SUBLICENSEES of any invention related to the TECHNOLOGY.

      12.2 MICHIGAN shall be entitled to participate at its option and expense
through counsel of its own selection, and can join in any legal actions related
to any such claims, demands, damages, losses and expenses under Paragraph 12.1
above.

      12.3 Prior to any distribution (including any distribution for clinical
trials) of any LICENSED PRODUCT by COULTER, AFFILIATES or SUBLICENSEES, COULTER
shall purchase and maintain in effect a policy of product liability insurance.
Such insurance policy shall provide for reasonable coverage for all claims with
respect to any LICENSED PRODUCTS manufactured, sold, sublicensed or distributed
and shall specify MICHIGAN, including its fellows, officers and employees, as an
additional insured. COULTER shall furnish certificate(s) of such insurance to
MICHIGAN, upon request.

      12.4 The requirements of defense and indemnity for events under Paragraph
12.1(ii) are not intended to apply to situations in which MICHIGAN might use
LICENSED PRODUCTS received from COULTER (or its AFFILIATES or SUBLICENSEES) and,
because of the manner of MICHIGAN's use (i.e., negligent or otherwise actionable
use), thereby cause damage to third parties.

13.   TERM AND TERMINATION.

      13.1 This Agreement will become effective on its EFFECTIVE DATE and will
remain in effect until and terminate upon the last to expire of LICENSED
PATENTS, unless terminated under another specific provision of this Agreement.

      13.2 Upon termination of this Agreement, all rights and obligations of the
PARTIES hereunder shall cease, except those terms, provisions, representations,
rights and obligations contained in this Agreement that by their sense and
context are intended to survive until performance, including:

            A. Obligations to pay royalties and other sums accruing to the day
of such termination;

            B. MICHIGAN's rights to inspect books and records as described in
ARTICLE 5, and COULTER's obligations to keep such records for the required time;

            C. Obligations of defense and indemnity in ARTICLE 12; and

                                       -9-
<PAGE>
            D. The general rights, understandings and obligations of Articles
11, 26 and 27.

      13.3 In the event that either PARTY shall default in the performance of
its obligation under this Agreement and shall fail to remedy such default within
[*] for breaches of financial obligations and [*] for breaches of non-financial
obligations after written notice from the other PARTY, the non defaulting PARTY
shall be entitled upon giving written notice to immediately terminate this
Agreement; provided however, that if the defaulting PARTY has undertaken and
continues to undertake, good faith efforts to cure, the defaulting PARTY shall
be granted another [*] to cure.

      13.4 COULTER can terminate this Agreement by giving MICHIGAN at least
[*] advance notice of termination. The notice shall be deemed by the
PARTIES to be final and upon receipt of the notice of termination, MICHIGAN
shall have the immediate right to enter into commercial agreements with others
for the manufacture sale, and/or use of LICENSED PRODUCTS, except that COULTER
does not guarantee or warrant that COULTER, or any other entity, will supply any
third party with [*]. Should COULTER choose to terminate this Agreement under
this Paragraph 13.4, it agrees [*].

14.   ASSIGNMENT.

      Due to the unique relationship between the PARTIES, this Agreement shall
not be assignable by either PARTY without the prior written consent of the other
PARTY. Any attempt to assign this Agreement without such consent shall be void
from the beginning. MICHIGAN shall not unreasonably withhold consent for COULTER
to assign this Agreement. No assignment shall be effective unless and until the
intended assignee agrees in writing to accept all of the terms and conditions of
this Agreement. [*].

15.   REGISTRATION AND RECORDATION.

      15.1 If this Agreement, any assignment or sublicense of this Agreement are
required to be registered or reported to a national or supranational agency in
an area in which COULTER, AFFILIATES or SUBLICENSEES would do business, COULTER
will undertake such registration or report at its own expense. Prompt notice and
appropriate verification of the act of registration or report or any agency
ruling resulting from it will be supplied by COULTER to MICHIGAN.

      15.2 Any formal recordation of this Agreement or any license or right
herein granted which is required by the law of any country, as a prerequisite to
enforceability of the Agreement or license or right in the courts of any such
country or for other reasons, shall also be carried out by COULTER at its
expense. Appropriately verified proof of recordation shall be promptly furnished
to MICHIGAN.

16.   CONFORMITY WITH LAW.

----------------------------
* Confidential treatment requested

                                      -10-
<PAGE>
      16.1 This Agreement, and COULTER's and its AFFILIATES' and SUBLICENSEES'
activities hereunder, shall to the best of COULTER's knowledge, be carried out
in strict compliance with all applicable federal, state and local laws and
regulation, including without limitation, laws and regulations related to equal
opportunity, animal welfare and immigration compliance, and related to the
export, testing, production, transportation, packaging, labeling, sale or use of
LICENSED PRODUCTS.

      16.2 COULTER shall obtain written assurances regarding export and
re-export of TECHNOLOGY and LICENSED PRODUCTS that is required by the Office of
Export Administration Regulations. COULTER will give the required written
assurances to MICHIGAN.

17.   RESTRICTION ON USE OF NAMES.

      Neither PARTY shall use the names of the other, its related entities, and
its employees or any adaptations thereof, in any advertising, promotional or
sales literature, without the prior written consent of the PARTY whose name is
being used in each case; provided however, a PARTY can:

            A. Refer to publications by employees of the other PARTY in the
scientific literature or reports in scientific literature and presentations of
joint research and development work, and

            B. State that a license has been granted as herein provided, as
required in financial reports and other non-commercial documents.

18.   PRODUCT MARKING.

      COULTER agrees to mark, and to require AFFILIATES and SUBLICENSEES to
mark, LICENSED PRODUCTS with an appropriate patent notice [*].

19.   NOTICES.

      19.1 Any notice, request, report or payment required or permitted to be
given or made under this agreement by either PARTY can be given by sending such
notice by certified or registered mail, return receipt requested, to the address
set forth below or such other address as such PARTY shall have specified by
written notice given in conformity herewith.

      19.2 Any notice given in accordance with the above provisions shall be
effective when mailed.

      19.3 Alternatively, notices may be sent by U.S. first class mail or by
courier, postage prepaid (where applicable), or by facsimile where promptly
confirmed by personal delivery via U.S. first class mail or courier, postage
prepaid, to the address set forth below or such other address as such PARTY
shall have specified by written notice given in conformity herewith; such
notices shall be effective only upon actual receipt by the addressee.

----------------------------
* Confidential treatment requested

                                      -11-
<PAGE>
      To MICHIGAN:            The University of Michigan
                              Technology Management Office
                              Wolverine Tower, Room 2071
                              3003 South State Street
                              Ann Arbor, MI  48109-1280
                               Attn: File No. 1009

      To COULTER:             Coulter Corporation
                              11800 S.W. 147 Avenue
                              Miami, Florida 33196
                              Attention: Ms. Bobbie Wallace

      With copy to:           Coulter Corporation
                              1800 S.W. 147 Avenue
                              Miami, Florida 33196
                              Attention: Corporate Counsel

20.   SEVERABILITY AND CONSTRUCTION.

      20.1 If any one or more of the provisions of the AGREEMENT shall be held
to be invalid, illegal or unenforceable, the validity, legality or
enforceability of the remaining provisions of this AGREEMENT shall not in any
way be affected or impaired thereby.

      20.2 The parties agree that they have participated equally in the
formation of this Agreement and that the language herein should not be
presumptively construed against either of them.

21.   ENTIRE AGREEMENT AND AMENDMENTS.

      This agreement contains the entire understanding of the PARTIES with
respect to the matter contained herein. The PARTIES can modify, vary or alter
any of the provisions of this agreement, by only by an instrument duly executed
by authorized officials of both PARTIES.

22.   WAIVER.

      No waiver by either PARTY of any breach of this Agreement shall be deemed
a waiver of any subsequent breach thereof nor shall any delay or omission on the
part of either PARTY to exercise any right, power, or privilege hereunder be
deemed a waiver of such right, power or privilege.

23.   ARTICLE HEADINGS.

      The ARTICLE headings herein are for purposes of convenient reference only
and shall not be used to construe or modify the terms of this Agreement.

                                      -12-
<PAGE>
24.   NO AGENCY RELATIONSHIP.

      For the purpose of this AGREEMENT and all services to be provided
hereunder, both PARTIES shall be independent contractors and not agents or
employees of the other. Neither PARTY shall have authority to make any
statements, representations or commitments of any kind, or to take any action,
that will be binding on the other PARTY.

25.   FORCE MAJEURE.

      If the performance of any part of this Agreement by either PARTY, or of
any obligation under this Agreement is prevented, restricted, interfered with or
delayed by reason of any cause beyond the reasonable control of the PARTY liable
to perform, unless reasonable evidence to the contrary is provided, the PARTY so
affected shall, upon giving written notice to the other PARTY, be excused from
such performance to the extent of such prevention, restriction, interference or
delay, provided that the affected PARTY shall use its reasonable efforts to
avoid or remove such causes for nonperformance and shall continue performance
with the utmost dispatch whenever such causes are removed. When such
circumstances arise, the PARTIES shall discuss what, if any, modification of the
terms of this Agreement may be required in order to arrive at an equitable
solution.

26.   GOVERNING LAW.

      This Agreement and the relationships between the Parties shall be governed
in all respect by the law of the state of Michigan (notwithstanding any
provisions governing conflict of laws under such Michigan law to the contrary),
except that questions affecting the construction and effect of any patent shall
be determined by the law of the country in which the patent has been granted.

27.   DISPUTE RESOLUTION.

      27.1 any controversy or claim arising out of, or relating to, any
provisions of this agreement or the breach thereof which cannot otherwise be
resolved by good faith negotiations between the PARTIES or by some form of
alternate dispute resolution other than arbitration shall be resolved by final
and binding arbitration in New York, New York under the rules of the American
Arbitration Association, or the Patent Arbitration Rules if applicable, then
obtaining.

      27.2 The arbitration shall be subject to the following terms:

            A. The number of arbitrators shall be one (1).

            B. The arbitrator shall be an independent, impartial third party
having no direct or indirect personal or financial relationship to any of the
parties to the dispute, who has agreed to accept the appointment as arbitrator
on the terms set out in this Section 27.

            C. The arbitrator shall be an active or retired attorney, law
professor, or judicial officer with at least five (5) years experience in
general commercial matters and a familiarity with the laws governing proprietary
rights in intellectual property and the TECHNOLOGY in dispute.

                                      -13-
<PAGE>
            D. The arbitrator shall be selected as follows:

                  (1) Each PARTY shall submit a description of the matter to be
arbitrated to the American Arbitration Association at its Regional office in New
York, New York. Said Association shall submit to the PARTIES a list for the
arbitrators available to arbitrate any dispute between them. Thereafter, each
PARTY shall select, in numerical order, those persons on said list acceptable as
arbitrators and return the same to the Association. The first arbitrator
acceptable to both PARTIES shall be deemed the selected arbitrator with respect
to the dispute then at issue under this Agreement. In the event of a failure to
select a mutually agreeable arbitrator, the Association shall be requested to
submit as many subsequent lists of arbitrators as shall be necessary to effect a
mutual selection.

                  (2) If the method of selection set out in paragraph D(1) fails
for any reason, then either PARTY may petition an appropriate state or federal
court for appointment of the arbitrator in accordance with applicable law,
provided that the arbitrator must satisfy the requirements of B and C, above.

            E. The arbitrator shall announce the award in writing accompanied by
written findings explaining the facts determined in support of the award, and
any relevant conclusions of law.

      27.3 Unless otherwise provided in this Section or extended by agreement of
the PARTIES, each PARTY shall submit an initial request for designation of an
arbitrator within [*] after any request for arbitration, the dispute shall be
submitted to the arbitrator within [*] after the arbitrator is selected, and a
decision shall be rendered within [*] after the dispute is submitted.

      27.4 The fees of the arbitrator and any other costs and fees associated
with the arbitration shall he paid in accordance with the decision of the
arbitrator.

      27.5 The arbitrator shall have no power to add to, subtract from, or
modify any of the terms or conditions of this Agreement. Any award rendered in
such arbitration may be enforced by either PARTY in the appropriate State or
United States District Court in the State of Michigan.

      27.6 Notwithstanding the foregoing, nothing in this Article shall be
construed to waive any rights or timely performance of any obligations existing
under this agreement.

----------------------------
* Confidential treatment requested

                                      -14-
<PAGE>
      IN WITNESS WHEREOF, the PARTIES hereto have executed this Agreement in
duplicate originals by their duly authorized officers or representatives.

COULTER INCORPORATED                    THE REGENTS OF THE
                                        UNIVERSITY OF MICHIGAN

By:  /s/ BOBBY F. WALLACE               By:  /s/ ROBERT L. ROBB
     -------------------------------         -------------------------------
     (authorized representative)             (authorized representative)

Typed Name: Bobby F. Wallace            Typed Name: Robert L. Robb

Title: Director of Immunology           Title: Director, Technology Management
                                         Office

                                      -15-
<PAGE>
                                    Exhibit A

                                       [*]

----------------------------
* Confidential treatment requested

                                      -16-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00047-of-00352.parquet"}]]